Zobrazeno 1 - 10
of 94
pro vyhledávání: '"David A Egan"'
Autor:
Carla S Verissimo, René M Overmeer, Bas Ponsioen, Jarno Drost, Sander Mertens, Ingrid Verlaan-Klink, Bastiaan van Gerwen, Marieke van der Ven, Marc van de Wetering, David A Egan, René Bernards, Hans Clevers, Johannes L Bos, Hugo J Snippert
Publikováno v:
eLife, Vol 5 (2016)
Colorectal cancer (CRC) organoids can be derived from almost all CRC patients and therefore capture the genetic diversity of this disease. We assembled a panel of CRC organoids carrying either wild-type or mutant RAS, as well as normal organoids and
Externí odkaz:
https://doaj.org/article/7501d8e3fc1b4a42aa7676d2bb0a2f09
Autor:
Lieke M. van der Velden, Peter Maas, Miranda van Amersfoort, Elpetra P M. Timmermans-Sprang, Anneloes Mensinga, Elisabeth van der Vaart, Fabrice Malergue, Henk Viëtor, Patrick W B. Derksen, Judith Klumperman, Andreas van Agthoven, David A. Egan, Jan A. Mol, Ger J. Strous
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
Growth hormone (GH) and insulin‐like growth factor‐1 (IGF1) play an important role in mammalian development, cell proliferation and lifespan. Especially in cases of tumor growth there is an urgent need to control the GH/IGF1 axis. In this study w
Externí odkaz:
https://doaj.org/article/6f999f5cbc62488d94457d2a397848c2
Autor:
Nikolaos Karantzelis, Michalis Petropoulos, Valeria De Marco, David A. Egan, Alexander Fish, Evangelos Christodoulou, David W. Will, Joe D. Lewis, Anastassis Perrakis, Zoi Lygerou, Stavros Taraviras
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
DNA replication initiation requires the loading of MCM2-7 complexes at the origins of replication during G1. Replication licensing renders chromatin competent for DNA replication and its tight regulation is essential to prevent aberrant DNA replicati
Externí odkaz:
https://doaj.org/article/a12e5a12cb4d47728c4807ff7f7cae4b
Autor:
M. Emmy M. Dolman, Jan J. Molenaar, Kelly C. Goldsmith, Jan Koster, Ronald W. Stam, Mark Kerstjens, David A. Egan, Daphne Lelieveld, Linda Schild, Nil A. Schubert, Hunter C. Jonus, Bianca Koopmans, Jasmine Y. Lee, Lindy K. Alles, Laurel T. Bate-Eya, Lindy Vernooij
Supplementary data including supplementary figures S1 to S6 and supplementary tables S1 to S3.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c19a6188349cc1e7ae304543adf5a25
https://doi.org/10.1158/1535-7163.22522524
https://doi.org/10.1158/1535-7163.22522524
Autor:
M. Emmy M. Dolman, Jan J. Molenaar, Kelly C. Goldsmith, Jan Koster, Ronald W. Stam, Mark Kerstjens, David A. Egan, Daphne Lelieveld, Linda Schild, Nil A. Schubert, Hunter C. Jonus, Bianca Koopmans, Jasmine Y. Lee, Lindy K. Alles, Laurel T. Bate-Eya, Lindy Vernooij
Supplementary information on the used materials and methods.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::737308f3d4a0e5a27d921f6744ac9ebf
https://doi.org/10.1158/1535-7163.22522521.v1
https://doi.org/10.1158/1535-7163.22522521.v1
Autor:
M. Emmy M. Dolman, Jan J. Molenaar, Kelly C. Goldsmith, Jan Koster, Ronald W. Stam, Mark Kerstjens, David A. Egan, Daphne Lelieveld, Linda Schild, Nil A. Schubert, Hunter C. Jonus, Bianca Koopmans, Jasmine Y. Lee, Lindy K. Alles, Laurel T. Bate-Eya, Lindy Vernooij
Neuroblastoma tumors frequently overexpress the anti-apoptotic protein B-cell lymphoma/leukemia 2 (BCL-2). We previously showed that treating BCL-2–dependent neuroblastoma cells with the BCL-2 inhibitor venetoclax results in apoptosis, but unfortun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a94290ce21ef15de16b10560ee4307a2
https://doi.org/10.1158/1535-7163.c.6543414.v1
https://doi.org/10.1158/1535-7163.c.6543414.v1
Autor:
Jos Jonkers, Peter Bouwman, Richard Wade-Martins, David J. Adams, Pauline Edser, Henne Holstege, David A. Egan, Tanya M. Braumuller, Eline van der Burg, Eva Schut, Bastiaan Evers
Purpose: Hereditary breast cancer is partly explained by germline mutations in BRCA1 and BRCA2. Although patients carry heterozygous mutations, their tumors have typically lost the remaining wild-type allele. Selectively targeting BRCA deficiency may
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::428e979414835e5edf813ea165f4f21e
https://doi.org/10.1158/1078-0432.c.6520677.v1
https://doi.org/10.1158/1078-0432.c.6520677.v1
Publikováno v:
FEBS Open Bio, Vol 5, Iss 1, Pp 85-90 (2015)
Novel spheroid‐type tumor cell cultures directly isolated from patients’ tumors preserve tumor characteristics better than traditionally grown cell lines. However, such cultures are not generally used for high‐throughput toxicity drug screens.
Externí odkaz:
https://doaj.org/article/7e14b9e6b8a34f479948720ead5d11cb
Autor:
Marja Jäättelä, David A. Egan, Christoffel Dinant, Tiina Naumanen Dietrich, Inger Ødum Nielsen, Maria Postol, Kenji Maeda, Siri Amanda Tvingsholm, Tuula Kallunki, Malene Hansen, Pietri Puustinen, Robert Strauss
Publikováno v:
Hansen, M B, Postol, M, Tvingsholm, S, Nielsen, I Ø, Dietrich, T N, Puustinen, P, Maeda, K, Dinant, C, Strauss, R, Egan, D, Jäättelä, M & Kallunki, T 2021, ' Identification of lysosome-targeting drugs with anti-inflammatory activity as potential invasion inhibitors of treatment resistant HER2 positive cancers ', Cellular Oncology, vol. 44, pp. 805–820 . https://doi.org/10.1007/s13402-021-00603-2
Cellular Oncology (Dordrecht)
Cellular Oncology (Dordrecht)
Purpose Most HER2 positive invasive cancers are either intrinsic non-responsive or develop resistance when treated with 1st line HER2 targeting drugs. Both 1st and 2nd line treatments of HER2 positive cancers are aimed at targeting the HER2 receptor
Autor:
Henk-Jan Prins, A. Koen Braat, D. Gawlitta, Wouter J.A. Dhert, David A. Egan, Estel Tijssen-Slump, Huipin Yuan, Paul J. Coffer, Henk Rozemuller, Anton C. Martens
Publikováno v:
Stem Cell Research, Vol 12, Iss 2, Pp 428-440 (2014)
One of the applications of bone marrow stromal cells (BMSCs) that are produced by ex vivo expansion is for use in in vivo bone tissue engineering. Cultured stromal cells are a mixture of cells at different stages of commitment and expansion capabilit
Externí odkaz:
https://doaj.org/article/0398fe5ae04e469992b169283e8ddf19